BNT162b2 Vaccine Effectiveness Against the SARS-CoV-2 Omicron Variant in Children Aged 5 to 11 Years-Reference-Cited by-同舟云学术

BNT162b2 Vaccine Effectiveness Against the SARS-CoV-2 Omicron Variant in Children Aged 5 to 11 Years

Published:2023-03-01 Issue:3 Volume:177 Page:319
ISSN:2168-6203
Container-title:JAMA Pediatrics
language:en
Short-container-title:JAMA Pediatr

Author:

Jang Eun Jung¹,Choe Young June²,Kim Ryu Kyung¹,Park Young-Joon¹

Affiliation:

1. Korea Disease Control and Prevention Agency, Cheongju, Korea

2. Korea University Anam Hospital, Seoul, Korea

Abstract

This cohort study examines data for all children aged 5 to 11 years in South Korea to gauge the effectiveness of the BNT162b2 vaccine when the Omicron variant was the dominant SARS-CoV-2 infection in the country.

Publisher

American Medical Association (AMA)

Subject

Pediatrics, Perinatology and Child Health

Link

https://jamanetwork.com/journals/jamapediatrics/articlepdf/2800322/jamapediatrics_jang_2023_ld_220050_1677804731.23639.pdf

Reference5 articles.

1. Coronavirus disease 2019 disease severity in children infected with the omicron variant.;Butt;Clin Infect Dis,2022

2. BNT162b2 vaccine effectiveness against omicron in children 5 to 11 years of age.;Cohen-Stavi;N Engl J Med,2022

3. Effectiveness of 2-dose BNT162b2 (Pfizer BioNTech) mRNA vaccine in preventing SARS-CoV-2 infection among children aged 5-11 years and adolescents aged 12-15 years: PROTECT cohort, July 2021-February 2022.;Fowlkes;MMWR Morb Mortal Wkly Rep,2022

4. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022.;Sacco;Lancet,2022

5. Effectiveness of BNT162b2 vaccine against omicron in children 5 to 11 years of age.;Tan;N Engl J Med,2022

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical characteristics of SARS-CoV-2-associated encephalopathy in children: Nationwide epidemiological study;Journal of the Neurological Sciences;2024-02

2. More common RNAemia in the early stage of severe SARS-CoV-2 BF.7.14 infections in pediatric patients;Biosafety and Health;2023-12

3. Clinical characteristics of abruptly increased paediatric patients with Omicron BF.7 or BA.5.2 in Beijing;Virology Journal;2023-09-08

4. Safety and effectiveness of vaccines against COVID-19 in children aged 5–11 years: a systematic review and meta-analysis;The Lancet Child & Adolescent Health;2023-06

5. Error in Author Affiliations;JAMA Pediatrics;2023-03-01